

Nonperturbative Fluorogenic Labeling of Immunophilins Enables the Wash-free Detection of Immunosuppressants

Marco Bertolini,[▽] Lorena Mendive-Tapia,[▽] Ouldouz Ghashghaei, Abigail Reese, Charles Lochenie, Anna M. Schoepf, Miquel Sintes, Karolina Tokarczyk, Zandile Nare, Andrew D. Scott, Stephen R. Knight, Advait R. Aithal, Amit Sachdeva, Rodolfo Lavilla,^{*} and Marc Vendrell^{*}



Cite This: *ACS Cent. Sci.* 2024, 10, 969–977



Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: Immunosuppressants are clinically approved drugs to treat the potential rejection of transplanted organs and require frequent monitoring due to their narrow therapeutic window. Immunophilins are small proteins that bind immunosuppressants with high affinity, yet there are no examples of fluorogenic immunophilins and their potential application as optical biosensors for immunosuppressive drugs in clinical biosamples. In the present work, we designed novel diazonium BODIPY salts for the site-specific labeling of tyrosine residues in peptides via solid-phase synthesis as well as for late-stage functionalization of whole recombinant proteins. After the optimization of a straightforward one-step labeling procedure for immunophilins PPIA and FKBP12, we demonstrated the application of a fluorogenic analogue of FKBP12 for the selective detection of the immunosuppressant drug tacrolimus, including experiments in urine samples from patients with functioning renal transplants. This chemical methodology opens new avenues to rationally design wash-free immunophilin-based biosensors for rapid therapeutic drug monitoring.



INTRODUCTION

Immunosuppressive drugs are widely used in clinics to avoid allograft rejection in patients undergoing organ transplantation.¹ Importantly, real-time monitoring of the systemic levels of immunosuppressants (e.g., tacrolimus) is essential because their concentrations need to be adjusted within a narrow therapeutic window for appropriate dosage.² For instance, reduced levels of immunosuppressants (i.e., in the low mM range) can lead to rejection of the transplanted organ, while excessive amounts result in medication-associated side effects, renal dysfunction, and an increased risk of infections.³ Immunoassays have been described as a strategy to optimize the dosage of immunosuppressive drugs.⁴ These assays are sensitive to low concentrations of the drug but are hampered by antibody cross-reactivity, batch-to-batch reproducibility, and the need for multistep labeling approaches.^{5,6} Label-free strategies (e.g., HPLC–MS analysis) can also be used for therapeutic drug monitoring, but those typically require sample preparation and have limited temporal resolution.⁷

With most optical technologies for therapeutic drug monitoring relying on antibody-based assays,^{8,9} there are few examples of fluorescent probes to detect immunosuppressive drugs in biosamples.^{10–13} In this regard, the site-specific labeling of peptides and proteins with fluorogenic dyes can be an effective strategy to generate turn-on probes for real-time analyte detection.^{14–22} Thus, we envisioned that the synthesis of

fluorogenic reporters based on whole immunophilins may represent a modular and versatile approach to detect immunosuppressive drugs in real time. Our group and others have reported fluorogenic probes to measure immune cell activity^{23–26} by flanking enzyme-responsive substrates with fluorophore-quencher pairs^{27–29} and by embedding environmentally sensitive BODIPY amino acids within targeted peptide sequences.³⁰ The preparation of these fluorogenic probes often requires solid-phase peptide synthesis (SPPS),^{31–34} which is not compatible with large proteins; in this work, we present a chemical strategy to prepare the first examples of fluorogenic immunophilins for the therapeutic monitoring of immunosuppressants.


The incorporation of fluorophores into proteins typically involves the derivatization of lysines (Lys) or cysteines;^{35–37} however, our group and others have shown that the labeling of aromatic residues (e.g., phenylalanine (Phe),³⁸ tryptophan (Trp)^{39–42}) can retain the bioactivity profile of native sequences.⁴³ In the present work, we designed a chemical

Received: December 20, 2023

Revised: February 26, 2024

Accepted: February 26, 2024

Published: March 18, 2024






Figure 1. Fluorogenic labeling of peptides and proteins. Trp- and Phe-BODIPY amino acids can be synthesized by palladium-catalyzed C–H activation and subsequently incorporated into peptides by SPPS. Diazonium BODIPYs can selectively label tyrosine residues in whole immunophilins under mild conditions to produce fluorogenic biosensors. PG: protecting group.

approach to selectively label tyrosine (Tyr) residues of immunophilins (e.g., FKBP12) with BODIPY fluorophores and applied them as fluorogenic probes for the detection of tacrolimus. This strategy is in principle applicable to different immunophilins and holds the potential to accelerate the rational design of fluorescent immunosensors for bioanalytical applications.

RESULTS AND DISCUSSION

Chemical Synthesis and Optimization of Diazonium BODIPY Fluorogens for Tyr Labeling. Immunophilins are a family of peptidylprolyl isomerase proteins with a high affinity for immunosuppressive drugs. Among all immunophilins reported to date, FK506-binding protein (FKBP12) and peptidylprolyl isomerase A (PPIA) are known to bind the clinically approved drugs tacrolimus and cyclosporin A, respectively.^{44,45} Given their high binding affinity, we decided to employ this family of proteins for the rational design of protein-based fluorogenic probes for the wash-free detection of clinically approved immunosuppressants.

Our group has optimized linker-free strategies to couple BODIPY fluorophores to aromatic amino acids (i.e., Trp or Phe)^{38,46} and subsequently employed them for the generation of fluorogenic peptides with turn-on emission properties (Figure

1);^{40–42} however, these building blocks cannot be readily incorporated into full protein structures, primarily due to the lack of aminoacyl-tRNA synthetases that recognize bulky fluorophores. Alternatively, we aimed to synthesize reactive BODIPY fluorogens that could site-specifically label proteins under physiological conditions. The group of Barbas III and others reported diazonium salts as suitable reagents to modify Tyr-containing proteins with chemical selectivity over other residues.^{47–49} This approach has been reported for the Tyr-directed modification of several biomolecules, including peptides and proteins,^{50–57} but it has not yet been reported as an effective means for direct BODIPY functionalization. Building on this reactivity profile, we designed the synthesis of stable diazonium BODIPY salts and subsequently employed them for the derivatization of Tyr amino acids in short peptides and whole proteins. We envisioned that this technology would allow us to (1) selectively attach small fluorogenic tags on Tyr residues in a one-step straightforward process and (2) avoid the disruption of the biomolecular recognition features of native peptides and proteins by means of a minimal azo bond linkage.

We designed the chemical synthesis of diazonium BODIPY analogues from the corresponding anilines, which were, in turn, obtained by the reduction of the nitro-functionalized derivatives (Figure 2). Nitro-BODIPY (1, Figure 2) and aniline BODIPY




Figure 2. Synthesis of diazonium BODIPY and Tyr-BODIPY adducts. Synthetic scheme for the preparation of Tyr-BODIPY amino acids. (Left) Representative fluorescence spectra of compound **4** (25 μ M) in phosphate buffer saline (PBS) and after incubation with increasing concentrations of phosphatidylcholine liposome suspensions (from 3.75 to 0.004 mg mL⁻¹ in PBS (excitation: 450 nm).




Figure 3. Fluorogenic labeling of peptides with diazonium BODIPY and Tyr-BODIPY. (a) Parallel synthetic strategies including late-stage derivatization of unprotected KLVYFAE (top) and SPPS using Fmoc-Tyr(BODIPY)-OH (bottom). (b) HPLC-MS traces of purified peptides using the two different synthetic approaches. (c) Representative time-course bright-field and fluorescence microscopy images (Movie S1 in [Supporting Information](#)) of self-aggregates formed by peptide **5** (100 μ M) before and after incubation with diazonium BODIPY (5 μ M) under wash-free imaging (excitation: 488 nm). Scale bar: 100 μ m.

(**2**, [Figure 2](#)) were synthesized by the adaptation of reported procedures.⁵⁸ Next, we made several attempts to obtain the diazonium BODIPY compound (**3**, [Figure 2](#)) by screening a variety of nitrite sources and acidic media. Initial attempts with sodium nitrite and hydrochloric acid or BF₃·Et₂O were not successful; instead, we found that the diazotization of compound **2** in aqueous HBF₄ with isoamyl nitrite afforded the desired diazonium salts by simple precipitation and in yields >70% ([Figure 2](#) and [Figure S1](#)). Of note, this synthetic strategy is scalable to hundreds of milligrams, and we confirmed that the diazonium salts can be safely stored as solids in sealed containers and under an inert atmosphere for over 2 years at -20 °C. To the best of our knowledge, this is the first example of an unsubstituted diazonium BODIPY fluorophore as a building block for the direct derivatization of peptides and proteins.

Next, we assessed the reaction of the diazonium BODIPY derivative with Fmoc-L-Tyr-OH in an aqueous medium ([Figure 2](#)). We observed good conversion rates at relatively short reaction times (e.g., around 1 h) under basic conditions using mixtures of H₂O and ACN, and Tyr-BODIPY adduct **4** was isolated in yields of around 40% ([Figure 2](#)). Furthermore, we corroborated that the basic conditions used in the coupling of diazonium BODIPYs did not cause any epimerization of the asymmetric carbon of L-Tyr-OH ([Figure S2](#)), which confirms the suitability of this approach for labeling peptides and proteins without affecting their chirality. In view of the good reactivity of diazonium BODIPYs against Tyr residues, we measured the optical properties of the Tyr-BODIPY adduct **4** and observed extinction coefficients and excitation/emission wavelengths similar to those of BODIPY dyes (e.g., 500 and 520 nm, respectively) in the green region of the visible spectrum ([Figures](#)




Figure 4. Optimization of whole immunophilin protein labeling using diazonium BODIPYs. (a) Tyrosine conjugation of the diazonium BODIPY to the immunophilin PPIA (PDB code: 1CWA). For simplicity, only one of the two native Tyr residues within the PPIA protein is illustrated. (b) In-gel fluorescence analysis of PPIA labeling reactions with different equivalents of diazonium BODIPY. D/P ratio: dye/protein ratio. (c) Peptide fragments identified by proteomic analysis after trypsin digestion of labeled PPIA. Residues detected by mass spectrometry are highlighted with the symbol ✓ whereas nondetected sequences are highlighted with the symbol ×.

S3 and S4). Interestingly, Tyr-BODIPY amino acid 4 displayed notable fluorogenicity, with a >20-fold fluorescence enhancement in increasing concentrations of phosphatidylcholine-based liposomes (Figure 2) and in dioxane (Figure S5), with very low background fluorescence emission in aqueous media.

Site-Specific Fluorogenic Labeling of Tyr-Containing Peptides. Given the properties of diazonium BODIPY as a reactive fluorogen for the derivatization of Tyr residues, we studied its application for labeling short peptides as simple model substrates. First, we analyzed the suitability of diazonium BODIPY for the late-stage modification of heptapeptide KLVYFAE (5, Figure 3). The KLVYFAE sequence is derived from the hydrophobic core of the β -amyloid protein (residues 16–22) and exhibits self-association into highly organized structures,⁵⁹ thus being a suitable model peptide to corroborate the fluorogenic behavior of Tyr-BODIPY given the inherent ability of KLVYFAE to form self-aggregates in aqueous media.

First, we employed conventional SPPS procedures to prepare the peptide KLVYFAE (150 mg scale, >95% purity; see Supporting Information for full synthetic details and characterization data). Using dynamic light scattering, we confirmed that the sequence formed aggregates in a concentration- and time-dependent manner (Figure S6). Next, we employed the free

peptide (i.e., without any side-chain protecting groups) for late-stage BODIPY derivatization. Reactions were conducted under basic conditions at 4 °C for 1 h, employing a slight excess (i.e., 1.2 equiv) of para-substituted diazonium BODIPY (compound 9, see Supporting Information). Finally, the labeled peptide was purified by semipreparative HPLC to yield KLVY(BODIPY)-FAE (6, Figure 3) with purities >95%.

In order to confirm the identity of the BODIPY-labeled peptide 6, we synthesized the same sequence using Fmoc-Tyr(BODIPY)-OH as a building block for SPPS. Given the lability of the BODIPY fluorophore to acidic media, we used Fmoc-Lys(Alloc)-OH and Fmoc-Glu(OAll)-OH as amino acids with Pd⁰-labile protecting groups and an acid-labile Sieber Amide polystyrene resin. We performed the synthesis with conventional SPPS procedures (e.g., DIC and OxymaPure for couplings, piperidine:DMF (2:8) for Fmoc removal, and TFA:DCM (1:99) for solid support cleavage) and isolated the BODIPY-modified peptide by semipreparative HPLC with purities >95%. Importantly, we verified that the two batches of BODIPY-labeled peptide 6 (i.e., late-stage derivatization vs SPPS) were identical by HPLC–MS (Figure 3), thus demonstrating that the conjugation of diazonium BODIPY took place exclusively at the Tyr residue.




Figure 5. Tyr-specific BODIPY labeling of FKBP12 enables selective fluorescence detection of tacrolimus. (a) Molecular docking illustration displaying the binding of tacrolimus (pink) to FKBP12 Y26F Y80F (blue) labeled with diazonium BODIPY (green). Computational analysis was conducted using DiffDock, and the results were visualized using ChimeraX (PDB code: 1KFJ). (b) Chemical structures of the immunosuppressive drugs tacrolimus and cyclosporin A. (c) Single-cycle kinetic SPR characterization of BODIPY-labeled FKBP12 Y26F Y80F interaction with increasing concentrations of tacrolimus. An 8-point dilution series was performed over a concentration range of 0.2 nM–0.5 μ M for tacrolimus. (d) Summary table of the kinetic parameters for SPR binding assays between tacrolimus and unlabeled FKBP12 Y26F Y80F or BODIPY-labeled FKBP12 Y26F Y80F proteins. (e) Fluorescence units' increase (520 nm) of BODIPY-labeled FKBP12 Y26F Y80F (1 μ M) upon binding to increasing concentrations of tacrolimus. Values obtained by subtraction of the emission signal of BODIPY-labeled FKBP12 Y26F Y80F in the presence of tacrolimus vs emission signal in the absence of tacrolimus, presented as means $\pm$ SEMs ($n = 3$). The limit of detection (determined as the mean of the blank value plus 3 times the standard deviation of the blank) is equal to 190 nM.

Having checked the suitability of diazonium BODIPY as a reagent for the derivatization of Tyr-containing peptides, we analyzed its potential as a reporter for real-time fluorescence imaging. For this purpose, we induced the formation of peptide 5-based aggregates and incubated them at pH 9 with diazonium BODIPY to visualize them with fluorescence microscopy. As shown in Figure 3c, the diazonium BODIPY brightly labeled the aggregates in minutes under wash-free conditions. As a negative control, we attempted the same labeling experiment under neutral conditions (pH 7, Figure S7); however, lower fluorescence signals were detected, which confirmed that Tyr-specific conjugation of the diazonium BODIPY led to enhanced turn-on emission due to restricted rotation once embedded in the aggregated peptide. Altogether, these results confirmed the suitability of Tyr-BODIPY as a building block for the fluorogenic derivatization of peptide sequences.

BODIPY-Labeled Immunophilins Enable Wash-free Detection of the Immunosuppressive Drug Tacrolimus.

Building on the results of BODIPY labeling in short peptides, next we optimized the direct coupling of diazonium BODIPY to immunophilins. For these experiments, we first employed commercially available immunophilin PPIA (peptidylprolyl isomerase A) as a model protein. PPIA is an 18 kDa protein with two Tyr residues in its primary sequence (e.g., Tyr47 and Tyr78); therefore, we envisaged that PPIA would be a suitable model immunophilin to assess the site selectivity of diazonium BODIPYs via fluorescence and proteomic experiments. First, we subjected PPIA to a series of conjugation reactions with increasing amounts of diazonium BODIPY (i.e., from 1 to 40 equiv) for 1 h at 4 $^{\circ}$ C. Successful BODIPY labeling of PPIA was verified by SDS-PAGE analysis and fluorescence scanning (Figure 4 and Figure S8). Although the labeling reactions

proceeded to some extent at equimolar concentrations, the formation of bright conjugates was optimal when using 5 equiv of the fluorophore (Figure 4). Interestingly, a large excess of diazonium BODIPY did not result in brighter protein bands and led to the formation of precipitates with reduced recovery yields. Following the removal of unreacted dye by ultrafiltration, we measured the degree of labeling (DoL) for all of the conditions and obtained DoL values of around 1 when 5 equiv of diazonium BODIPY was used (Figure 4). We also examined the site selectivity of the diazonium BODIPY conjugation by the analysis of the labeled PPIA using mass spectrometry. Importantly, we confirmed BODIPY labeling at Tyr residues (Figure 4), and no conjugation to other aromatic amino acids (e.g., Phe, Trp) was detected (Figures S9 and S10). These results align with the preferential coupling of diazonium salts on tyrosines over more hindered tryptophans and histidines in a protein context.^{47,57} Altogether, these results validated the utility of diazonium BODIPY for the direct labeling of Tyr residues in whole immunophilins using a straightforward procedure.

Having optimized the procedure for the Tyr-specific conjugation of BODIPY fluorogens in whole immunophilins, we applied our methodology to protein FKBP12. FKBP12 is a 12 kDa immunophilin that binds to the immunosuppressive drugs tacrolimus and rapamycin, which are macrolides lacking chromophoric groups and cannot be readily detected using conventional optical measurements (Figure 5). First, we analyzed the crystal structure of the complex between human FKBP12 and tacrolimus.^{60,61} The wild-type FKBP12 protein (WT FKBP12) contains three Tyr residues (i.e., Tyr26, Tyr80, and Tyr82), of which the latter is in close proximity to the tacrolimus binding site. We envisaged that the diazonium BODIPY labeling of Tyr82 would (1) retain the ability of

FKBP12 to bind tacrolimus with high affinity and (2) incorporate a suitable fluorogen for enhanced turn-on emission upon binding; therefore, we designed a FKBP12 mutant (FKBP12 Y26F Y80F) retaining the native Tyr residue at position 82 and replacing the Tyr26 and Tyr80 residues with Phe (Figure 5). We expressed the FKBP12 Y26F Y80F protein by cloning the DNA fragment corresponding to FKBP12 Y26F Y80F into the pSANG10 plasmid⁶² (Figure S11) and performing protein expression in *E. coli* BL21(pLysS) cells. Cells were lysed by sonication, and the FKBP12 Y26F Y80F protein was purified via the C-terminal 6×His tag (Figure S12). Furthermore, we performed surface plasmon resonance (SPR) binding assays between immobilized FKBP12 Y26F Y80F protein and increasing concentrations of tacrolimus (0.2 nM to 0.5 μ M, experimental details in Supporting Information) and observed that the immunophilin retained a high binding affinity for tacrolimus, with K_D values of around 30 nM (Figure S13).

Using our previously optimized labeling procedure, we then reacted the immunophilin FKBP12 Y26F Y80F with the diazonium BODIPY 3 and obtained DoL values of around 1 (experimental details in the Supporting Information). Importantly, we confirmed by SPR that the BODIPY-labeled FKBP12 Y26F Y80F protein exhibited equally strong binding to tacrolimus (K_D = 45 nM, Figure 5) and excellent selectivity over other immunosuppressants (i.e., cyclosporin A) that do not bind FKBP12⁶³ (Figure S14), thus asserting the nonperturbative character of this labeling approach to generate natively like fluorogenic proteins. Next, we examined the fluorescence response of BODIPY-labeled FKBP12 Y26F Y80F after incubation with tacrolimus and cyclosporin A as well as other small molecules (e.g., amino acids, lipids, and sugars). Notably, BODIPY-labeled FKBP12 Y26F Y80F showed strong fluorescence emission after incubation with tacrolimus but not in the presence of cyclosporin A and other biological metabolites (Figure S15). These results are in agreement with the *in vitro* fluorogenicity observed for Tyr-BODIPY (Figure 2), which confirms that the fluorescence emission of labeled immunophilins can be enhanced upon drug binding due to the local increase in hydrophobicity.⁶⁴ Enhanced steric hindrance upon binding may also contribute to the fluorogenic behavior by promoting the restriction of the BODIPY rotation along the phenyl coordinate, leading to a decrease in nonradiative decay, as previously shown in other BODIPY fluorophores.⁶⁵ Other nonradiative transitions such as *cis/trans* isomerization of the azobenzene moiety may also be contributing factors as reported for other azobenzenes structures.^{66,69} Furthermore, in order to corroborate that Tyr82 was a suitable residue for monitoring the binding of FKBP12 to tacrolimus, we employed the same experimental conditions to label the WT FKBP12 protein as a negative control. In this case, the presence of different Tyr amino acids led to reduced sensitivity for tacrolimus (Figure S16), highlighting the suitability of Tyr82 as an optimal labeling site at the tacrolimus-binding interface.

Finally, we employed the BODIPY-labeled FKBP12 Y26F Y80F in titration assays with tacrolimus and observed a clear dose response reaching saturation levels at equimolar concentrations of protein and a limit of detection of 190 nM (Figure 5). Furthermore, we applied the fluorogenic FKBP12 Y26F Y80F for the detection of tacrolimus in urine samples from renal transplant patients undergoing organ rejection. For these experiments, we analyzed a small collection of biosamples from patients that presented with renal transplant acute kidney injury (AKI) and had been prescribed a twice-daily oral

preparation of tacrolimus (Prograf). All patients had been taking tacrolimus for a minimum of 4 weeks, with doses ranging between 1 and 6 mg, and had stable transplant function prior to their AKI. Notably, we observed brighter fluorescence responses of BODIPY-labeled FKBP12 in urine samples from patients when compared to healthy controls (Figure S17). These results indicate the potential application of fluorogenic FKBP12 analogues for the direct detection of immunosuppressive drugs in clinical biosamples and demonstrate that the rational design of site-specific BODIPY-labeled immunophilins is an effective strategy to generate fluorogenic probes for wash-free therapeutic drug monitoring.

CONCLUSIONS

We report the first chemical synthesis of unsubstituted diazonium BODIPY fluorophores as building blocks for the direct derivatization of Tyr amino acids in complex biomolecules. Diazonium BODIPY can be conveniently synthesized by diazotization of the corresponding aniline using commercial reagents in good yields. We demonstrated its utility for the modification of Tyr-containing peptide sequences, such as the self-assembling amyloid peptide KLVYFAE, using conventional SPPS and late-stage protocols, as well as the application to wash-free and real-time microscopy experiments. Furthermore, we optimized the one-step direct coupling of diazonium BODIPY to whole immunophilin proteins under physiological conditions, affording the first fluorogenic analogues of FKBP12. The rational design of a fluorogenic FKBP12 probe where the fluorophore was site-specifically introduced at the tacrolimus-binding interface retained a natively like selectivity profile and enabled the wash-free detection of nanomolar concentrations of the immunosuppressive drug tacrolimus, including experiments in clinical biosamples from renal transplant patients. The chemical simplicity, modularity, and versatility of this fluorogenic protein labeling strategy have the potential to accelerate the molecular engineering of fluorescent immunophilins for bioanalytical applications.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acscentsci.3c01590>.

Detailed synthetic procedures and full chemical characterization data, methods, supplementary figures, and NMR and IR spectra, and description of Movie S1 (PDF)

Movie S1: time-lapse fluorogenic labeling of peptide aggregates with compound 9 (AVI)

Transparent Peer Review report available (PDF)

AUTHOR INFORMATION

Corresponding Authors

Rodolfo Lavilla – Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine UB (IBUB), University of Barcelona, Catalunya, Spain 08007; orcid.org/0000-0002-5006-9917; Email: rlavilla@ub.edu

Marc Vendrell – Centre for Inflammation Research, The University of Edinburgh, EH16 4UU Edinburgh, U.K.; IRR Chemistry Hub, Institute for Regeneration and Repair, The University of Edinburgh, EH16 4UU Edinburgh, U.K.; orcid.org/0000-0002-5392-9740; Email: marc.vendrell@ed.ac.uk

Authors

Marco Bertolini – Centre for Inflammation Research, The University of Edinburgh, EH16 4UU Edinburgh, U.K.; IRR Chemistry Hub, Institute for Regeneration and Repair, The University of Edinburgh, EH16 4UU Edinburgh, U.K.; orcid.org/0000-0003-2609-9515

Lorena Mendive-Tapia – Centre for Inflammation Research, The University of Edinburgh, EH16 4UU Edinburgh, U.K.; IRR Chemistry Hub, Institute for Regeneration and Repair, The University of Edinburgh, EH16 4UU Edinburgh, U.K.

Ouldouz Ghashghaei – Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine UB (IBUB), University of Barcelona, Catalunya, Spain 08007; orcid.org/0000-0002-5524-3697

Abigail Reese – Centre for Inflammation Research, The University of Edinburgh, EH16 4UU Edinburgh, U.K.; IRR Chemistry Hub, Institute for Regeneration and Repair, The University of Edinburgh, EH16 4UU Edinburgh, U.K.

Charles Lochenie – Centre for Inflammation Research, The University of Edinburgh, EH16 4UU Edinburgh, U.K.; IRR Chemistry Hub, Institute for Regeneration and Repair, The University of Edinburgh, EH16 4UU Edinburgh, U.K.

Anna M. Schoepf – Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine UB (IBUB), University of Barcelona, Catalunya, Spain 08007

Miquel Sintes – Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine UB (IBUB), University of Barcelona, Catalunya, Spain 08007

Karolina Tokarczyk – Concept Life Sciences Ltd, Edinburgh Bioquarter, Edinburgh EH16 4UX, U.K.

Zandile Nare – Concept Life Sciences Ltd, Edinburgh Bioquarter, Edinburgh EH16 4UX, U.K.; orcid.org/0009-0007-5701-8323

Andrew D. Scott – Concept Life Sciences Ltd, Edinburgh Bioquarter, Edinburgh EH16 4UX, U.K.

Stephen R. Knight – Renal Transplant Unit, Queen Elizabeth Hospital, Glasgow G51 4TF, U.K.

Advait R. Aithal – School of Chemistry, University of East Anglia, Norwich NR4 7TJ, U.K.

Amit Sachdeva – School of Chemistry, University of East Anglia, Norwich NR4 7TJ, U.K.; orcid.org/0000-0002-3704-5750

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acscentsci.3c01590>

Author Contributions

[†]M.B. and L.M.-T. contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

L.M.-T. acknowledges funding from the Wellcome Trust Institutional Strategic Support Fund (ISSF) at the University of Edinburgh. O.G. acknowledges support through the Eurolife Postdoc Mobility and Knowledge Exchange Program. A.M.S. thanks the Austrian Science Fund (FWF) for the project J4541-N. A.R.A. is funded by the NRP-BBSRC-Doctoral Training Programme. S.R.K. acknowledges funding from a Kidney Research UK Stoneygate Startup award (KS_SU_002_20221129). A.S. acknowledges funding from the University of East Anglia. R.L. acknowledges the Ministerio de Ciencia e Innovación (Spain), the European Regional

Development Fund (EDFR) (PID2022-139180OB-I00), and Generalitat de Catalunya (Research Quality groups SGR-DGR 00357). M.V. acknowledges funds from an ERC Consolidator Grant (DYNAFLUORS, 771443). The authors acknowledge the EdinOmics research facility (RRID: SCR_021838, University of Edinburgh) for carrying out the mass spectrometry analyses of the proteins. This project has received funding from the European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement (956477). For open access, the authors applied a CC-BY public copyright license to any Author Accepted Manuscript version arising from this submission. The authors acknowledge BioRender.com for assistance with figure creation and Silvia Dotto for the graphical design and creation of the cover art.

REFERENCES

- (1) Halloran, P. F. Immunosuppressive drugs for kidney transplantation. *N. Engl. J. Med.* **2004**, *351*, 2715–2729.
- (2) Capron, A.; Lerut, J.; Latinne, D.; Rahier, J.; Haufrond, V.; Wallemacq, P. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. *Transpl. Int.* **2012**, *25*, 41–47.
- (3) Pillans, P. I.; Rigby, R. J.; Kubler, P.; Tett, S. E.; Willis, C.; Taylor, P. J. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. *Clin. Biochem.* **2001**, *34*, 77–81.
- (4) Zhang, Y.; Zhang, R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. *Drug Test. Anal.* **2018**, *10*, 81–94.
- (5) Murthy, J. N.; Davis, D. L.; Yatscoff, R. W.; Soldin, S. J. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. *J. Clin. Biochem.* **1998**, *31*, 613–617.
- (6) Toraiishi, T.; Takeuchi, H.; Nakamura, Y.; Konno, O.; Yokoyama, T.; Iwamoto, H.; Hama, K.; Hirano, T.; Unezaki, S.; Okuyama, K.; et al. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report. *Transplant. Proc.* **2012**, *44*, 134–136.
- (7) Christians, U.; Vinks, A. A.; Langman, L. J.; Clarke, W.; Wallemacq, P.; Gelder, T. V.; Renjen, V.; Marquet, P.; Meyer, E. J. Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs. *Ther. Drug Monit.* **2015**, *37*, 718–724.
- (8) Berrettoni, C.; Berneschi, S.; Bernini, R.; Giannetti, A.; Grimaldi, I. A.; Persichetti, G.; Testa, G.; Tombelli, S.; Trono, C.; Baldini, F. Optical monitoring of therapeutic drugs with a novel fluorescence-based POCT device. *Procedia Eng.* **2014**, *87*, 392–395.
- (9) Coentrao, L.; Carvalho, C.; Sampaio, S.; Oliveira, J. G.; Pestana, M. I. Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay. *Transplant. Proc.* **2010**, *42*, 1867–1869.
- (10) Yang, L.; Ge, J.; Ma, D.; Tang, J.; Wang, H.; Li, Z. MoS(2) quantum dots as fluorescent probe for methotrexate detection. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* **2022**, *279*, No. 121443.
- (11) Glahn-Martinez, B.; Lucchesi, G.; Pradanas-Gonzalez, F.; Manzano, A. I.; Canales, A.; Caminati, G.; Benito-Pena, E.; Moreno-Bondi, M. C. Biosensing tacrolimus in human whole blood by using a drug receptor fused to the emerald green fluorescent protein. *Anal. Chem.* **2022**, *94*, 16337–16344.
- (12) Tamura, T.; Kioi, Y.; Miki, T.; Tsukiji, S.; Hamachi, I. Fluorophore labeling of native FKBP12 by ligand-directed tosyl chemistry allows detection of its molecular interactions in vitro and in living cells. *J. Am. Chem. Soc.* **2013**, *135*, 6782–6785.
- (13) Cornea, R. L.; Nitu, F. R.; Samsó, M.; Thomas, D. D.; Fruen, B. R. Mapping the ryanodine receptor FK506-binding protein subunit using

fluorescence resonance energy transfer. *J. Biol. Chem.* **2010**, *285*, 19219–19226.

(14) Zhang, Y.; He, S.; Chen, W.; Liu, Y.; Zhang, X.; Miao, Q.; Pu, K. Activatable polymeric nanoprobe for near-infrared fluorescence and photoacoustic imaging of T lymphocytes. *Angew. Chem., Int. Ed.* **2021**, *60*, 5921–5927.

(15) He, S.; Cheng, P.; Pu, K. Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. *Nat. Biomed. Eng.* **2023**, *7*, 281–297.

(16) Zeng, Z.; Liew, S. S.; Wei, X.; Pu, K. Hemicyanine-based near-infrared activatable probes for imaging and diagnosis of diseases. *Angew. Chem., Int. Ed.* **2021**, *60*, 26454–26475.

(17) Akram, A. R.; Avlonitis, N.; Scholefield, E.; Vendrell, M.; McDonald, N.; Aslam, T.; Craven, T. H.; Gray, C.; Collie, D. S.; Fisher, A. J.; et al. Enhanced avidity from a multivalent fluorescent antimicrobial peptide enables pathogen detection in a human lung model. *Sci. Rep.* **2019**, *9*, 8422.

(18) Venkatraman, P.; Nguyen, T. T.; Sainlos, M.; Bilsel, O.; Chitta, S.; Imperiali, B.; Stern, L. J. Fluorogenic probes for monitoring peptide binding to class II MHC proteins in living cells. *Nat. Chem. Biol.* **2007**, *3*, 222–228.

(19) Alamudi, S. H.; Satapathy, R.; Kim, J.; Su, D.; Ren, H.; Das, R.; Hu, L.; Alvarado-Martinez, E.; Lee, J. Y.; Hoppmann, C.; et al. Development of background-free tame fluorescent probes for intracellular live cell imaging. *Nat. Commun.* **2016**, *7*, 11964.

(20) Kowada, T.; Maeda, H.; Kikuchi, K. BODIPY-based probes for the fluorescence imaging of biomolecules in living cells. *Chem. Soc. Rev.* **2015**, *44*, 4953–4972.

(21) Duffet, L.; Williams, E. T.; Gresch, A.; Chen, S.; Bhat, M. A.; Benke, D.; Hartampf, N.; Patriarchi, T. Optical tools for visualizing and controlling human GLP-1 receptor activation with high spatiotemporal resolution. *eLife* **2023**, *12*, No. RP86628.

(22) Ghashghaei, O.; Caputo, S.; Sintes, M.; Reves, M.; Kielland, N.; Estarellas, C.; Luque, F. J.; Avino, A.; Eritja, R.; Serna-Gallego, A.; et al. Multiple multicomponent reactions: unexplored substrates, selective processes, and versatile chemotypes in biomedicine. *Chem.—Eur. J.* **2018**, *24*, 14513–14521.

(23) Fernandez, A.; Vermeren, M.; Humphries, D.; Subiros-Funosas, R.; Barth, N.; Campana, L.; MacKinnon, A.; Feng, Y.; Vendrell, M. Chemical modulation of in vivo macrophage function with sub-population-specific fluorescent prodrug conjugates. *ACS Cent. Sci.* **2017**, *3*, 995–1005.

(24) Mellanby, R. J.; Scott, J. I.; Mair, I.; Fernandez, A.; Saul, L.; Arlt, J.; Moral, M.; Vendrell, M. Tricarbocyanine N-triazoles: the scaffold-of-choice for long-term near-infrared imaging of immune cells in vivo. *Chem. Sci.* **2018**, *9*, 7261–7270.

(25) Fernandez, A.; Thompson, E. J.; Pollard, J. W.; Kitamura, T.; Vendrell, M. A fluorescent activatable AND-gate chemokine CCL2 enables in vivo detection of metastasis-associated macrophages. *Angew. Chem., Int. Ed.* **2019**, *58*, 16894–16898.

(26) He, S.; Li, J.; Lyu, Y.; Huang, J.; Pu, K. Near-infrared fluorescent macromolecular reporters for real-time imaging and urinalysis of cancer immunotherapy. *J. Am. Chem. Soc.* **2020**, *142*, 7075–7082.

(27) Scott, J. I.; Mendive-Tapia, L.; Gordon, D.; Barth, N. D.; Thompson, E. J.; Cheng, Z.; Taggart, D.; Kitamura, T.; Bravo-Blas, A.; Roberts, E. W.; et al. A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies. *Nat. Commun.* **2022**, *13*, 2366.

(28) Kolt, S.; Janiszewski, T.; Kaiserman, D.; Modrzycka, S.; Snipas, S. J.; Salvesen, G.; Drag, M.; Bird, P. I.; Kasperkiewicz, P. Detection of active granzyme A in NK92 Cells with fluorescent activity-based probe. *J. Med. Chem.* **2020**, *63*, 3359–3369.

(29) Scott, J. I.; Gutkin, S.; Green, O.; Thompson, E. J.; Kitamura, T.; Shabat, D.; Vendrell, M. A functional chemiluminescent probe for in vivo imaging of natural killer cell activity against tumours. *Angew. Chem., Int. Ed.* **2021**, *60*, 5699–5703.

(30) Mendive-Tapia, L.; Subiros-Funosas, R.; Zhao, C.; Albericio, F.; Read, N. D.; Lavilla, R.; Vendrell, M. Preparation of a Trp-BODIPY

fluorogenic amino acid to label peptides for enhanced live-cell fluorescence imaging. *Nat. Protoc.* **2017**, *12*, 1588–1619.

(31) Zhao, C.; Fernandez, A.; Avlonitis, N.; Vande Velde, G.; Bradley, M.; Read, N. D.; Vendrell, M. Searching for the optimal fluorophore to label antimicrobial peptides. *ACS Comb. Sci.* **2016**, *18*, 689–696.

(32) Yraola, F.; Ventura, R.; Vendrell, M.; Colombo, A.; Fernández, J. C.; de la Figuera, N.; Fernández-Fórner, D.; Royo, M.; Forn, P.; Albericio, F. A Re-evaluation of the use of Rink, BAL, and PAL resins and linkers. *QSAR Comb. Sci.* **2004**, *23*, 145–152.

(33) Vendrell, M.; Angulo, E.; Casadó, V.; Lluís, C.; Franco, R.; Albericio, F.; Royo, M. Novel ergopeptides as dual ligands for adenosine and dopamine receptors. *J. Med. Chem.* **2007**, *50*, 3062–3069.

(34) Hamze, A.; Martinez, J.; Hernandez, J.-F. Solid-phase synthesis of arginine-containing peptides and fluorogenic substrates using a side-chain anchoring approach. *J. Org. Chem.* **2004**, *69*, 8394–8402.

(35) Barth, N. D.; Van Dalen, F. J.; Karmakar, U.; Bertolini, M.; Mendive-Tapia, L.; Kitamura, T.; Verdoes, M.; Vendrell, M. Enzyme-activatable chemokine conjugates for in vivo targeting of tumor-associated macrophages. *Angew. Chem., Int. Ed.* **2022**, *61*, No. e202207508.

(36) de Lorimier, R. M.; Smith, J. J.; Dwyer, M. A.; Looger, L. L.; Sali, K. M.; Paavola, C. D.; Rizk, S. S.; Sadigov, S.; Conrad, D. W.; Loew, L.; et al. Construction of a fluorescent biosensor family. *Protein Sci.* **2002**, *11*, 2655–2675.

(37) Bernardes, G. J. L.; Chalker, J. M.; Errey, J. C.; Davis, B. G. Facile conversion of cysteine and alkyl cysteines to dehydroalanine on protein surfaces: versatile and switchable access to functionalized proteins. *J. Am. Chem. Soc.* **2008**, *130*, 5052–5053.

(38) Mendive-Tapia, L.; Mendive-Tapia, D.; Zhao, C.; Gordon, D.; Benson, S.; Bromley, M. J.; Wang, W.; Wu, J.; Kopp, A.; Ackermann, L.; et al. Rational design of Phe-BODIPY amino acids as fluorogenic building blocks for peptide-based detection of urinary tract candida infections. *Angew. Chem., Int. Ed.* **2022**, *61*, No. e202117218.

(39) Subiros-Funosas, R.; Ho, V. C. L.; Barth, N. D.; Mendive-Tapia, L.; Pappalardo, M.; Barril, X.; Ma, R.; Zhang, C. B.; Qian, B. Z.; Sintes, M.; et al. Fluorogenic Trp (redBODIPY) cyclopeptide targeting keratin 1 for imaging of aggressive carcinomas. *Chem. Sci.* **2020**, *11*, 1368–1374.

(40) Subiros-Funosas, R.; Mendive-Tapia, L.; Sot, J.; Pound, J. D.; Barth, N.; Varela, Y.; Goni, F. M.; Paterson, M.; Gregory, C. D.; Albericio, F.; Dransfield, I.; Lavilla, R.; Vendrell, M. A Trp-BODIPY cyclic peptide for fluorescence labelling of apoptotic bodies. *Chem. Commun.* **2017**, *53*, 945–948.

(41) Barth, N. D.; Subiros-Funosas, R.; Mendive-Tapia, L.; Duffin, R.; Shields, M. A.; Cartwright, J. A.; Henriques, S. T.; Sot, J.; Goni, F. M.; Lavilla, R.; et al. A fluorogenic cyclic peptide for imaging and quantification of drug-induced apoptosis. *Nat. Commun.* **2020**, *11*, 4027.

(42) Kaplaneris, N.; Son, J.; Mendive-Tapia, L.; Kopp, A.; Barth, N. D.; Maksso, I.; Vendrell, M.; Ackermann, L. Chemodivergent manganese-catalyzed C-H activation: modular synthesis of fluorogenic probes. *Nat. Commun.* **2021**, *12*, 3389.

(43) de Moliner, F.; Konieczna, Z.; Mendive-Tapia, L.; Saleeb, R. S.; Morris, K.; Gonzalez-Vera, J. A.; Kaizuka, T.; Grant, S. G. N.; Horrocks, M. H.; Vendrell, M. Small fluorogenic amino acids for peptide-guided background-free imaging. *Angew. Chem., Int. Ed.* **2023**, *62*, No. e202216231.

(44) Handschumacher, R. E.; Harding, M. W.; Rice, J.; Drugge, R. J.; Speicher, D. W. Cyclophilin A: a specific cytosolic binding protein. *Science* **1984**, *226*, 544–547.

(45) Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. A receptor for the immunosuppressant FK506 is a cis–trans peptidyl-prolyl isomerase. *Nature* **1989**, *341*, 758–760.

(46) Mendive-Tapia, L.; Zhao, C.; Akram, A. R.; Preciado, S.; Albericio, F.; Lee, M.; Serrels, A.; Kielland, N.; Read, N. D.; Lavilla, R.; et al. Spacer-free BODIPY fluorogens in antimicrobial peptides for direct imaging of fungal infection in human tissue. *Nat. Commun.* **2016**, *7*, 10940.

- (47) Gavriluk, J.; Ban, H.; Nagano, M.; Hakamata, W.; Barbas, C. F., III Formylbenzene diazonium hexafluorophosphate reagent for tyrosine-selective modification of proteins and the introduction of a bioorthogonal aldehyde. *Bioconjugate Chem.* **2012**, *23*, 2321–2328.
- (48) Gavriluk, J.; Ban, H.; Uehara, H.; Sirk, S. J.; Saye-Francisco, K.; Cuevas, A.; Zablowsky, E.; Oza, A.; Seaman, M. S.; Burton, D. R.; et al. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. *J. Virol.* **2013**, *87*, 4985–4993.
- (49) Bernardim, B.; Dunsmore, L.; Li, H.; Hocking, B.; Nuñez-Franco, R.; Navo, C. D.; Jiménez-Osés, G.; Burtoloso, A. C. B.; Bernardes, G. J. L. Precise installation of diazo-tagged side-chains on proteins to enable in vitro and in-cell site-specific labeling. *Bioconj. Chem.* **2020**, *31*, 1604–1610.
- (50) Schlick, T. L.; Ding, Z.; Kovacs, E. W.; Francis, M. B. Dual-surface modification of the tobacco mosaic virus. *J. Am. Chem. Soc.* **2005**, *127*, 3718–3723.
- (51) Jones, M. W.; Mantovani, G.; Blindauer, C. A.; Ryan, S. M.; Wang, X.; Brayden, D. J.; Haddleton, D. M. Direct peptide bioconjugation/PEGylation at tyrosine with linear and branched polymeric diazonium salts. *J. Am. Chem. Soc.* **2012**, *134*, 7406–7413.
- (52) Alvarez Dorta, D.; Deniaud, D.; Mevel, M.; Gouin, S. G. Tyrosine conjugation methods for protein labelling. *Chem.—Eur. J.* **2020**, *26*, 14257–14269.
- (53) Declas, N.; Maynard, J. R. J.; Menin, L.; Gasilova, N.; Gotze, S.; Sprague, J. L.; Stallforth, P.; Matile, S.; Waser, J. Tyrosine bioconjugation with hypervalent iodine. *Chem. Sci.* **2022**, *13*, 12808–12817.
- (54) Szijj, P. A.; Kostadinova, K. A.; Spears, R. J.; Chudasama, V. Tyrosine bioconjugation - an emergent alternative. *Org. Biomol. Chem.* **2020**, *18*, 9018–9028.
- (55) Cheng, M. H. Y.; Savoie, H.; Bryden, F.; Boyle, R. W. A facile and controllable conjugation method for the labelling of BSA with multiwavelength BODIPYs as potential imaging agents for use in fluorescence guided imaging. *Photochem. Photobiol. Sci.* **2017**, *16*, 1260–1267.
- (56) Leier, S.; Richter, S.; Bergmann, R.; Wuest, M.; Wuest, F. Radiometal-containing aryl diazonium salts for chemoselective bioconjugation of tyrosine residues. *ACS Omega* **2019**, *4*, 22101–22107.
- (57) Sengupta, S.; Chandrasekaran, S. Modifications of amino acids using arene-diazonium salts. *Org. Biomol. Chem.* **2019**, *17*, 8308–8329.
- (58) Hansen, J. S.; Petersen, J. F.; Hoeg-Jensen, T.; Christensen, J. B. Buffer and sugar concentration dependent fluorescence response of a BODIPY-based aryl monoboronic acid sensor. *Tetrahedron Lett.* **2012**, *53*, 5852–5855.
- (59) Pachahara, S. K.; Nagaraj, R. Probing the role of aromatic residues in the self-assembly of Aβ(16–22) in fluorinated alcohols and their aqueous mixtures. *Biochem. Biophys. Rep.* **2015**, *2*, 1–13.
- (60) Wilson, K. P.; Yamashita, M. M.; Sintchak, M. D.; Rotstein, S. H.; Murcko, M. A.; Boger, J.; Thomson, J. A.; Fitzgibbon, M. J.; Black, J. R.; Navia, M. A. Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin. *Acta Crystallogr. D Biol. Crystallogr.* **1995**, *51*, 511–521.
- (61) DeCenzo, M. T.; Park, S. T.; Jarrett, B. P.; Aldape, R. A.; Futer, O.; Murcko, M. A.; Livingston, D. J. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. *Protein Eng. Des. Sel.* **1996**, *9*, 173–180.
- (62) Bridge, T.; Shaikh, S. A.; Thomas, P.; Botta, J.; McCormick, P. J.; Sachdeva, A. Site-specific encoding of photoactivity in antibodies enables light-mediated antibody-antigen binding on live cells. *Angew. Chem., Int. Ed.* **2019**, *58*, 17986–17993.
- (63) Sabatini, D. M.; Lai, M. M.; Snyder, S. H. Neural roles of immunophilins and their ligands. *Mol. Neurobiol.* **1997**, *15*, 223–239.
- (64) Dorh, N.; Zhu, S.; Dhungana, K. B.; Pati, R.; Luo, F.-T.; Liu, H.; Tiwari, A. BODIPY-Based fluorescent probes for sensing protein surface-hydrophobicity. *Sci. Rep.* **2015**, *5*, 18337.
- (65) Lee, S.; Heo, J.; Woo, H. C.; Lee, J.-A.; Seo, Y. H.; Lee, C.-L.; Kim, S.; Kwon, O.-P. Fluorescent molecular rotors for viscosity sensors. *Chem.—Eur. J.* **2018**, *24*, 13706–13718.
- (66) Xue, L.; Pan, Y.; Zhang, S.; Chen, Y.; Yu, H.; Yang, Y.; Mo, L.; Sun, Z.; Li, L.; Yang, H. Fluorescent azobenzene-containing compounds: from structure to mechanism. *Crystals* **2021**, *11*, 840.
- (67) Crespi, S.; Simeth, N. A.; Konig, B. Heteroaryl azo dyes as molecular photoswitches. *Nat. Rev. Chem.* **2019**, *3*, 133–146.
- (68) Albert, L.; Nagpal, J.; Steinchen, W.; Zhang, L.; Werel, L.; Djokovic, N.; Ruzic, D.; Hoffarth, M.; Xu, J.; Kaspereit, J.; et al. Bistable photoswitch allows in vivo control of hematopoiesis. *ACS Cent. Sci.* **2022**, *8*, 57–66.
- (69) Morstein, J.; Romano, G.; Hetzler, B. E.; Plante, A.; Haake, C.; Levitz, J.; Trauner, D. Photoswitchable serotonin for optical control of the 5-HT_{2A} receptor. *Angew. Chem., Int. Ed.* **2022**, *61*, No. e202117094.